the significant effect of Acomplia(R) in reducing
intra-abdominal adipose tissue as measured by
October 1, 2007 Announcement that the FDA had approved Taxotere(R) for
the treatment of locally-advanced head and neck cancer
prior to chemoradiotherapy and surgery.
October 2, 2007 Announcement of the launch of Xyzal(R) on the U.S.
market by UCB and sanofi-aventis.
October 18, 2007 Announcement that the FDA had approved Menactra(R) for
children aged 2 through 10 years.
October 22, 2007 Announcement of extension to the indications of
Plavix(R) in Japan to patients with acute coronary
syndrome for whom percutaneous coronary intervention
October 22, 2007 Announcement of positive opinion from the Committee
for Medicinal Products for Human Use recommending
approval of Taxotere(R) in the European Union as an
induction treatment for locally advanced head and neck
October 24, 2007 Announcement of results from a new study that showed
patients with chronic insomnia who were treated with
Ambien CR(R) experienced significant improvements in
two key parameters of work performance.
October 24, 2007 Announcement of publication in the New England Journal
of Medicine of results of two clinical studies on
Taxotere(R), TAX 324 and TAX323.
December 10, 2007 Presentation of the results of the TREK dose-response
Copyright©2007 PR Newswire.
All rights reserved